Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02826486
Title Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT)
Acronym COMBAT
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BioLineRx, Ltd.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR | ESP


No variant requirements are available.